Safety of raloxifene in hemodialysis patients - Wikidata - wikimedia - TriplyDB

Safety of raloxifene in hemodialysis patients

Safety of raloxifene in hemodialysis patients

http://www.wikidata.org/entity/Q36957432

about

Safety of raloxifene in hemodialysis patients

http://www.wikidata.org/entity/Q36957432

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Safety of raloxifene in hemodialysis patients

@en

type

label

Safety of raloxifene in hemodialysis patients

@en

prefLabel

Safety of raloxifene in hemodialysis patients

@en

P1433

Q36957432-002039BF-06CA-42AC-82D9-D8BD05198D2E

P1476

Q36957432-1A0552FA-D1D5-4B7E-B143-7151E9D5CA8C

P2093

Q36957432-13FCA732-376F-4B64-BF9D-375CECE2BAC3

P2860

Q36957432-1369663D-6A5C-40FC-AC32-EEC56AA05F28

Q36957432-1F3979F9-1956-470A-A541-5111A71F0304

Q36957432-39AAEEF4-DF45-4E6B-A8C9-39423588ECC9

Q36957432-43BDE0BB-7B83-41CC-92E2-DC51823F4F0A

Q36957432-9607F4EA-4E0E-4250-A3F3-911374BAF688

Q36957432-AA3C0B92-0721-4565-8408-24F41743AC69

Q36957432-C81BC5C7-7C0C-477D-B55E-6EA04DA4C1F0

Q36957432-F79EFCC5-0F15-4B7C-ADB9-48C50A4A88DB

Q36957432-F99363E1-8F1D-4AF2-B042-7EEB2019B345

P304

Q36957432-48FFBFF8-34DD-4197-A9C1-AD38F807A471

P31

Q36957432-62AFE55B-7F6C-4B23-9A7F-6A6989A3F7AF

P356

Q36957432-05387144-7505-48D0-9153-834055805A8C

P433

Q36957432-E11F9AB4-939F-4F8F-876D-CCBC6288A17E

P478

Q36957432-8C121950-1289-4668-8FFA-353AC847CBE6

P577

Q36957432-149A008E-056F-4FCD-93C5-4CF99CCF4F5C

P5875

Q36957432-B45628FD-90B7-4035-A3AF-053B1D8AFC54

P698

Q36957432-0FAADC18-6797-4464-9975-0CF6D12BA536

P932

Q36957432-20AD08BC-FC90-4759-A3D9-7F6DA98567EF

P356

P1433

International journal of endocrinology and metabolism

P1476

Safety of raloxifene in hemodialysis patients

@en

P2093

Didy Jacobsen

http://www.w3.org/2001/XMLSchema#string

P2860

Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study.

Coronary heart disease risk factors in the elderly.

Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes

KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).

Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series.

Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study.

Raloxifene and risk for stroke based on the framingham stroke risk score.

Cardiovascular disease and chronic renal disease: a new paradigm.

An updated coronary risk profile. A statement for health professionals.

P304

638-639

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5812/IJEM.6285

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

248397649

http://www.w3.org/2001/XMLSchema#string

P698

23843838

http://www.w3.org/2001/XMLSchema#string

P932

3693647

http://www.w3.org/2001/XMLSchema#string